=Ab s t r a c t = Meningococcal infections can be associated with abnormalities of the complement system, which contains 5 terminal complement proteins. Furthermore, deficiencies in 1 of these 5, complement component 7 (C7), leads to the loss of complement lytic function, and affected patients show increased susceptibility to recurrent meningococcal meningitis and systemic Neisseria gonorrhoeae infection. In September 2003, an 11-year-old female patient presented at our outpatient department with high fever, lower leg pain, headache, and petechiaes. She rapidly progressed to coma but later achieved full recovery due to prompt treatment. Her final diagnosis was meningococcal sepsis and arthritis. Her elder brother also had a similar bacterial meningoencephalitis history, which encouraged us to perform analyses for complement component and gene mutations. Resultantly, both the brother and sister were found to have the same mutation in the C7 gene. Subsequently, vaccinations of the meningococcal vaccine meningococcal vaccine (Menomune Ⓡ ) were administered. However, in September 2006, the brother expired due to acute micrococcus meningoencephalitis. At present, the 16-year-old female patient is healthy. Here, we report a Korean family with a hereditary C7 deficiency with susceptibility to meningococcal infections due to C7 gene mutation. ( 
I n t r o d u c t i o n
Meningococcal infections may be associated with complement system abnormalities 1) . Genetically determined deficiencies of any of the terminal complement components are associated with increased risk to recurrent systemic infections primarily by Neisseria meningitides during the age range 10-30 years 2, 3) , when anti-meningococcal antibodies are presumed present 4) . Complement component 7 (C7) is one of five terminal complement proteins that upon activation of either the classical or the alternative complement pathway interacts sequentially to form a large protein-protein complex, called membrane attack complex (MAC). The assembly of MAC on target cells results in the formation of transmembrane pores that can lead to cell death 5, 6) . The single polypeptide chain of C7 is composed of 821 amino acid residues and is structurally similar to those of the other MAC components, C6, C8α, C8β, and C9 7, 8) . The C7 gene has been shown to span about 80kb of DNA and to be encoded by 18 exons 8) .
It is located on chromosome 5p13, as are the genes that encode C6 and C9 9) . C7 deficiency leads to the loss of complement lytic function, and patients so affected, show increased susceptibility to recurrent meningococcal meningitis and systemic Neisseria gonorrheae infections, although many siblings that share the deficiency may remain healthy 10) .
We report a Korean family with a hereditary C7 deficiency conferring susceptibility to meningococcal infection due to a G-to-T transversion (g.IVS4-1G>T) at the 3' splice acceptor site of intron 4 of the C7 gene.
Ca s er e p o r t
A 11-year-old girl was admitted via outpatient department in August 2003 with a high fever, headache, a right lower leg pain, and petechiae and 3 hours after admittance rapidly progressed to a comatose state. Upon initial physical examination, her body temperature was 39.6℃, heart rate 95 beat/minute, blood pressure was 100/70 mmHg. A Fig. 1 . Pedigree of the family with a C7 deficiency. The solid circle and square represents the patient (proband) and her brother, and the hemisolid square represents the carrier. The mother was normal. Sequencing analyses of C7 were not performed in other family members. Germany), revealed that her parents were at slightly lower than the normal level, but the patient and her brother were confirmed to be C7 deficient (Table 1) This mutation is the same as that reported in another Korean family 11) . In the present study, the father was heterozygous and patient and brother were homozygous (Fig. 2) .
After discharge, she intermittently visited outpatient de-partment because of a mild fever, a migraine headache, and a skin rash. Therefore, we decided that prophylactic menin- 
Di s c u s s i o n
The complement system is composed of a series of 19 plasma and 9 membrane proteins, and was first discovered at the turn of the twentieth century. However, it was not until the 1960's that the first complement deficient patient was described. The complement system is usually divided into classical and alternative pathways.
The incidences of complement deficiencies are both geographically and ethnically dependent 1) . C2 deficiencies are common in the USA, and C6 and C8α-γ deficiencies are common in blacks, whereas C7 and C8 deficiencies are predominantly observed in Caucasians. C9 deficiencies are common in Japan, and C7 deficiencies have been reported more frequently in Spain and Israel than in Japan and Korea 11) . Thus, the thresholds used for screening complement abnormalities should reflect these epidemiologic variations.
Deficiencies in the terminal components C5-C9 cause poor bactericidal function, especially of Neisseria species, and are the components needed to form MAC (membrane attack complex). Late component deficient patients in the US population may have a 1,000 to 10,000 fold increased risk of infection, with a median age at onset in the mid-teens, as compared to the first five years in the normal population.
Furthermore, those affected were found to have a relapse rate of approximately 8% and a recurrence rate of 44% 1, 12) .
C7 is a single-chain polypeptide composed of 821 amino acid residues and is structurally similar to other components of MAC, that is, C6, C8, C8, and C9 7, 8, 11) . The C7 gene spans about 80 kd of DNA and is encoded by 18 exons 8) . To date, more than 15 different molecular defects that lead to total or subtotal C7 deficiency have been reported 5, 11, 13) . . PSV-4 was developed in response to an increasing rate of bacterial meningitis among military recruits, and following the widespread use of vaccine in the military, a dramatic decrease in the incidence of invasive meningococcal disease has been observed 14) . However, PSV-4 is limited by its poor immunogenicity in small infants, a failure to induce a T-cell-dependent immune response, and a lack of long-term protection. In contrast, the novel tetravalent conjugate meningococcal vaccine, which currently is only available in North America, is immunogenic in young infants, induces long-term protection, and reduces nasopharyngeal carriage 15) . A tetravalent conjugate meningococcal vaccine was 
